December 09, 2016
1 min read
Save

A quarter of patients with limited UC have disease extension over time

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

ORLANDO — About a quarter of patients with limited ulcerative colitis have colonic disease extension over time, mostly within the first 10 years of disease onset, according to a systematic review and meta-analysis presented at AIBD 2016.

“Rate of extension depends on age at diagnosis and geographic origin and it occurs mostly during the first 10 years,” Giulia Roda, MD, PhD, from the Icahn School of Medicine at Mount Sinai, New York, told Healio Gastroenterology. “Predicting those at high risk of disease extension from diagnosis could lead to personalized therapeutic strategies.”

Giulia Roda

Jean-Frédéric Colombel

To determine the rate of disease extension in patients with limited UC at diagnosis, Roda and colleagues, including Jean-Frédéric Colombel, MD, searched for relevant epidemiological studies published through April 2015, identified 40 and ultimately analyzed 28.

At 5 years, the cumulative risk for colonic extension was 18.8%, and at 10 years it was 31.1%. From E1 to E3, extension was 27% (95% CI, 24.1-30.2), from E2 to E3, extension was 27.5% (95% CI, 24.1-31.5), and from E2 to E3 it was 22.9% (95% CI, 19.7-26.4).

The age of diagnosis, based on data from 13 studies, was 37.3 years, and the rate of extension was 27.5% (95% CI, 24.5-30.8) higher in patients aged younger then the median at diagnosis compared with older patients (16.8%; 95% CI, 15.6-18.1; P < .0001).

North American patients also had a significantly higher risk for extension compared with European patients (52% vs. 20.1%; P < .0001). – by Adam Leitenberger

Reference:

Roda G, et al. Abstract P-050. Presented at: Advances in Inflammatory Bowel Diseases; Dec. 8-10, 2016; Orlando, Fla.

Disclosures: Roda reports no relevant financial disclosures.